Sola Diagnostics
Innsbruck
About Sola Diagnostics
Product: Sola Diagnostics’ WID®-easy test is a non-invasive epigenetic solution for detecting endometrial cancer in women with abnormal uterine bleeding. Analyzing DNA methylation markers from a simple vaginal swab offers high accuracy, reducing false positives and unnecessary surgeries. Target Audience: Designed for gynecologists and healthcare providers, WID®-easy streamlines diagnostics, cutting costs and false alarms. Women benefit from a painless, accessible test that enables earlier, more precise detection. Technology: Powered by advanced DNA methylation research, WID®-easy identifies cancer-specific epigenetic markers. With PCR-based analysis and robust clinical validation, it delivers fast, reliable results that integrate seamlessly into medical workflows. Market Positioning: WID®-easy fills a critical gap as a first-line diagnostic for abnormal uterine bleeding. Its clinical validation, accuracy, and cost-efficiency set it apart from invasive procedures. Its ease of use and scalability position it for widespread adoption. Milestones: Sola Diagnostics launched in Austria and Switzerland in 2024 and expanded to Great Britain and Germany in 2025. UKCA Marking was registered in December 2024. So far, private equity investments totaling €3.4M have supported Sola's mission to revolutionize women’s health diagnostics. Moreover, NIHR has provided a GBP 2.2 million grant for a market access study in the UK.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $6.4M
- Funding stage: Seed
- Last round: Seed (Oct 2025)
- Website: sola-diagnostics.comen
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Diagnostics
Social Profiles
Canonical: https://fsome.com/organization/sola-diagnostics-55145 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.